Oral Agonist Treatment for Opioid Use Disorder

Case Study: Dr. Edward Rooke, M.D., CCFP

Main Presentation: Dr. Annabel Mead, MBBS FAChAM DABAM

Share this video:
Scroll to Top

The British Columbia Centre for Excellence in HIV/AIDS Laboratory has discontinued gp-41 resistance testing as T-20 (enfuvirtide/Fuzeon) is no longer available in Canada as of March 31, 2025